Cincinnati—University of Cincinnati (UC) physician-scientists believe identifying a genetic “fingerprint” could help predict which specific therapies will be most effective for patients with gastric cancer. Syed Ahmad, MD, is leading a national, phase-2 trial to test the effectiveness of combined chemotherapy and radiation therapy given to patients with gastric cancer before surgery. His team will also collect biological samples in an attempt to obtain genetic data that could be used to formulate targeted therapies.
